{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:42:38Z","timestamp":1783183358504,"version":"3.54.6"},"reference-count":17,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.24078","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T22:07:06Z","timestamp":1748556426000},"page":"84-92","source":"Crossref","is-referenced-by-count":1,"title":["Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients"],"prefix":"10.3960","volume":"65","author":[{"given":"Kiyoshi","family":"Okazuka","sequence":"first","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan,"},{"name":"Division of Hematology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tawara","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceutical Company Limited, Tokyo, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Ichihara","sequence":"additional","affiliation":[{"name":"ICON Clinical Research GK, Osaka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dumitru AV, \u021a\u0103poi DA, Halcu G <i>et al.<\/i> The polyvalent role of CD30 for cancer diagnosis and treatment. Cells. 2023; 12: 1783.","DOI":"10.3390\/cells12131783"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Connors JM, Jurczak W, Straus DJ <i>et al.<\/i> Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018; 378: 331-344.","DOI":"10.1056\/NEJMoa1708984"},{"key":"3","unstructured":"3 Takeda Pharmaceutical Company Limited. Takeda obtains additional indication and dosage &amp; administration for ADCETRIS<sup>\u00ae<\/sup> as a frontline treatment for CD30-positive Hodgkin lymphoma in Japan. 2018. https:\/\/www.takeda.com\/newsroom\/newsreleases\/2018\/takeda-obtains-additional-indication-and-dosage--administration-for-adcetris--as-a-frontline-treatment-for-cd30-positive-hodgkin-lymphoma-in-japan\/ (last access: 7 March 2024)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Ansell SM, Radford J, Connors JM <i>et al.<\/i> Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2022; 387: 310-320.","DOI":"10.1056\/NEJMoa2206125"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Ansell SM, Straus DJ, Connors JM <i>et al.<\/i> Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III\/IV classical Hodgkin lymphoma. J Clin Oncol. 2024; 42: 7053.","DOI":"10.1200\/JCO.2024.42.16_suppl.7053"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Forero-Torres A, Holkova B, Goldschmidt J <i>et al.<\/i> Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015; 126: 2798-2804.","DOI":"10.1182\/blood-2015-06-644336"},{"key":"7","unstructured":"7 Pharmaceuticals and Medical Devices Agency. Review Report: August 3, 2018. https:\/\/www.pmda.go.jp\/files\/000230125.pdf (last access: 7 March 2024)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Straus DJ, D\u0142ugosz-Danecka M, Alekseev S <i>et al.<\/i> Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood. 2020; 135: 735-742.","DOI":"10.1182\/blood.2019003127"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Straus D, Collins G, Walewski J <i>et al.<\/i> Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III\/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma. 2020; 61: 2931-2938.","DOI":"10.1080\/10428194.2020.1791846"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Kumano S. [GPSP: good post-marketing study practice] [in Japanese]. Nihon Yakurigaku Zasshi. 2012; 140: 81-84.","DOI":"10.1254\/fpj.140.81"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Cheson BD, Pfistner B, Juweid ME <i>et al.<\/i> Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Stark GL, Wood KM, Jack F <i>et al.<\/i> Hodgkin\u2019s disease in the elderly: a population-based study. Br J Haematol. 2002; 119: 432-440.","DOI":"10.1046\/j.1365-2141.2002.03815.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Proctor SJ, Wilkinson J, Jones G <i>et al.<\/i> Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood. 2012; 119: 6005-6015.","DOI":"10.1182\/blood-2011-12-396556"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Engert A, Ballova V, Haverkamp H <i>et al.<\/i> Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group. J Clin Oncol. 2005; 23: 5052-5060.","DOI":"10.1200\/JCO.2005.11.080"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Evens AM, Connors JM, Younes A <i>et al.<\/i> Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica. 2022; 107: 1086-1094.","DOI":"10.3324\/haematol.2021.278438"},{"key":"16","unstructured":"16 Takeda Pharmaceutical Company Limited. ADCETRIS\u00ae for I.V. Infusion 50mg (version 4, revised November 2023) [package insert] [in Japanese]. 2023. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_4291425D1021_1_14 (last access: 7 March 2024)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Sureda A, Domingo-Domenech E, Gautam A. Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management. Crit Rev Oncol Hematol. 2019; 138: 1-5.","DOI":"10.1016\/j.critrevonc.2019.03.016"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_24078\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:45:42Z","timestamp":1751085942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/2\/65_24078\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24078","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"24078"}}